5 Drugs Stocks Moving The Industry Upward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 31 points (0.2%) at 15,006 as of Tuesday, July 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,611 issues advancing vs. 1,325 declining with 103 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.4%. Top gainers within the industry include Shire ( SHPG), up 1.3%, and GlaxoSmithKline ( GSK), up 0.5%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Valeant Pharmaceuticals International is up $0.56 (0.6%) to $88.56 on average volume. Thus far, 738,861 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $88.07-$89.37 after having opened the day at $89.25 as compared to the previous trading day's close of $88.00.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $28.6 billion and is part of the health care sector. Shares are up 47.2% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year